Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials.

Publication Type:

Journal Article


Journal of the National Cancer Institute, Volume 103, Issue 19, p.1469-75 (2011)


2011, Aged, Confounding Factors (Epidemiology), Estrogen Replacement Therapy, Estrogens, Conjugated (USP), Female, Humans, Incidence, Kaplan-Meier Estimate, Medroxyprogesterone Acetate, MELANOMA, Menopause, Middle Aged, November 2011, Odds Ratio, Proportional Hazards Models, Public Health Sciences Division, Risk Assessment, Risk Factors, Skin Neoplasms, Women's Health


Case-control studies have reported that exogenous estrogen use is associated with increased risk of skin cancer. The effects of menopausal hormone therapy on incidence of nonmelanoma skin cancer and melanoma were evaluated in post hoc analyses of the Women's Health Initiative randomized placebo-controlled hormone therapy trials of combined estrogen plus progestin (E + P) and estrogen only (E-alone).